Gsk annual debt-to-assets ratio
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Gsk's debt-to-assets ratio was 0.25 for fiscal 2025.
View full Gsk company overview| Fiscal year | Period ended | Debt-to-assets ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.25 | 0.01 | +4.73% |
| 2024 | 2024-12-31 | 0.24 | −0.04 | −13.29% |
| 2023 | 2023-12-31 | 0.28 | −0.03 | −9.03% |
| 2022 | 2022-12-31 | 0.30 | 0.04 | +14.82% |
| 2021 | 2021-12-31 | 0.26 | −0.01 | −3.17% |
| 2020 | 2020-12-31 | 0.27 | −0.05 | −14.77% |
| 2019 | 2019-12-31 | 0.32 | −0.05 | −14.31% |
| 2018 | 2018-12-31 | 0.37 | 0.14 | +59.48% |
| 2017 | 2017-12-31 | 0.23 | 0.00 | +0.04% |
| 2016 | 2016-12-31 | 0.23 | — | — |
| Fiscal quarter | Period ended | Debt-to-assets ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.30 | 0.00 | +0.87% |
| Q1 2026 | 2026-03-31 | 0.30 | — | — |
| Q4 2025 | 2025-12-31 | 0.25 | 0.01 | +4.73% |
| Q3 2025 | 2025-09-30 | 0.29 | — | — |
| Q2 2025 | 2025-06-30 | 0.29 | — | — |
| Q4 2024 | 2024-12-31 | 0.24 | −0.04 | −13.29% |
| Q4 2023 | 2023-12-31 | 0.28 | −0.03 | −9.03% |
| Q4 2022 | 2022-12-31 | 0.30 | 0.04 | +14.82% |
| Q4 2021 | 2021-12-31 | 0.26 | −0.01 | −3.17% |
| Q4 2020 | 2020-12-31 | 0.27 | −0.05 | −14.77% |
| Q4 2019 | 2019-12-31 | 0.32 | −0.05 | −14.31% |
| Q4 2018 · Dec 31 | 2018-12-31 | 0.37 | 0.14 | +59.48% |
| Q4 2017 · Dec 31 | 2017-12-31 | 0.23 | −0.08 | −26.51% |
| Q4 2016 | 2016-12-31 | 0.32 | — | — |
Over the last five fiscal years, Gsk's debt-to-assets ratio decreased from 0.27 to 0.25, a change of −0.02. The latest reported quarter, Q2 2026, shows 0.30.
The debt-to-assets ratio shows the portion of a company’s reported assets financed with interest-bearing debt. It is a leverage measure and should not be confused with total liabilities divided by assets.
TickerStat calculates debt-to-assets as total interest-bearing debt divided by total assets at the same reporting-period end. Periods with missing debt or non-positive assets are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Gsk source filings ↗